share_log

PureTech Health Plc (OTCMKTS:PTCHF) Short Interest Up 26.3% in November

PureTech Health Plc (OTCMKTS:PTCHF) Short Interest Up 26.3% in November

PureTech Health Plc(OTCMKTS: PTCHF)11月份空头利率上涨26.3%
Financial News Live ·  2022/12/14 19:41

PureTech Health plc (OTCMKTS:PTCHF – Get Rating) was the recipient of a large increase in short interest during the month of November. As of November 30th, there was short interest totalling 159,100 shares, an increase of 26.3% from the November 15th total of 126,000 shares. Based on an average daily volume of 10,300 shares, the days-to-cover ratio is presently 15.4 days.

PureTech Health Plc(场外交易市场代码:PTCHF-GET Rating)是11月份空头股数大幅增长的接受者。截至11月30日,空头股数共有15.91万股,比11月15日的12.6万股增加了26.3%。以日均成交量10,300股计算,目前天数与回补比率为15.4天。

PureTech Health Price Performance

PureTech健康性价比

Shares of PTCHF remained flat at $3.40 during midday trading on Wednesday. The company's stock had a trading volume of 3,707 shares, compared to its average volume of 6,311. PureTech Health has a twelve month low of $1.83 and a twelve month high of $4.14. The business has a fifty day simple moving average of $2.89 and a 200 day simple moving average of $2.63.

在周三午盘交易中,PTCHF的股价持平于3.40美元。该公司股票的成交量为3,707股,而其平均成交量为6,311股。PureTech Health的12个月低点为1.83美元,12个月高位为4.14美元。该业务的50日简单移动均线切入位为2.89美元,200日简单移动均线切入位为2.63美元。

Get
到达
PureTech Health
PureTech Health
alerts:
警报:

PureTech Health Company Profile

PureTech Health公司简介

(Get Rating)

(获取评级)

PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions.
PureTech Health plc是一家临床阶段的生物治疗公司,在美国发现、开发和销售治疗炎症、纤维化和免疫、顽固性癌症、淋巴和胃肠道、神经和神经心理以及其他疾病的药物。该公司提供靶向M胆碱乙酰胆碱受体的KarXT,用于治疗阿尔茨海默病的精神分裂症和精神病;用于治疗雄激素性脱发、上皮老化和其他疾病的再生生物学平台;用于治疗慢性和急性炎症性疾病的免疫调节平台;用于从人体微生物群中分离出基于特定细菌群的口服疗法;以及用于治疗与抑郁症、多发性硬化症、COVID后和ICU以及癌症相关疾病相关的认知功能障碍的疗法。

Further Reading

进一步阅读

  • Get a free copy of the StockNews.com research report on PureTech Health (PTCHF)
  • Mullen Automotive Shares Jump After Signing New Partner
  • REV Group Leads Specialty Vehicle Manufacturers Higher
  • NVIDIA vs AMD: Which is better for 2023?
  • Will Nordstrom Stock be the Grinch This Year?
  • Harpoon Therapeutics Remains Volatile After Promising News
  • 免费获取StockNews.com关于PureTech Health(PTCHF)的研究报告
  • 马伦汽车签署新合作伙伴后股价上涨
  • REV集团引领专用车制造商走高
  • NVIDIA VS AMD:2023年哪一种更好?
  • 诺德斯特龙股票公司会成为今年的格林奇吗?
  • 鱼叉治疗公司在有希望的消息传出后仍不稳定

Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.

获得PureTech HealthDaily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对PureTech Health和相关公司的最新新闻和分析师评级的每日简要摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发